Lonza's SSP for Early Phase Delivery
Keywords:Cgmp, Cmo, Investment, Lonza, Small-scale plant
AbstractLonza, the leading custom manufacturer of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries, has recently expanded into a new state-ofthe-art seven-storey small-scale plant (SSP) whose task is to satisfy both clinical supply and process development with sophisticated and lean cGMP-compliant equipment. With this investment, Lonza has now closed the gap between kilo lab and launch plant in order to provide one-stop shopping for API and drug product developmentthrough-approval.
How to Cite
B. Schmidt, Chimia 2005, 59, 16, DOI: 10.2533/000942905777676885.
Copyright (c) 2005 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.